NRNP 6665 Final Exam | NR 603
Week 7
(2026-2027)
Complete Questions and Answers(Verified) |
Updated | Grade A+
,Question 18: A. Dissociative disorders
Christine is a 9-year-old female who presents for care after B. Post-traumatic stress disorder
having been placed in the local foster care system. She C. Impulse-control disorder
has been in and out of foster care for the last 4 years after D. Attachment disorder
her parents were killed in an automobile accident.
Christine has been placed in a variety of homes and
residential care facilities. The PMHNP recognizes that
Christine is at high risk for:
Question 7: A. Caylee is at high risk for suicide and precautions should be taken
Caylee is a 5-year-old girl who is referred for evaluation by B. The hallucinations are consistent with brief psychotic disorder or schizophrenia
child protective services. She was recently removed from C. The history and reported symptoms are typical of depressive disorder in young
her biological family and placed in foster care, as her home children
environment was reportedly unsafe due to conditions of D. This is a common situation when prepubertal children are removed from the
extreme neglect. Her foster mother reports that Caylee is biological parents regardless of how dysfunctional they are
very quiet and withdrawn and always appears sad and
disinterested in her surroundings; however, she becomes
very irritable when anything unexpected or unplanned
occurs. The foster mother became very concerned when it
appeared that Caylee was hallucinating. The PMHNP
considers that:
Question 2: A. There is a > 50% likelihood that Debi's younger sibling will develop depressive
Debi is a 15-year-old girl who is currently being treated for symptoms
depression. Her parents have been very proactive and B. The mean length of major depressive episode in adolescents is 4 months
involved in her care, and Debi has achieved remission 2 C. 20 to 40% of adolescents who have major depressive disorder will develop
months after beginning treatment with a combination of bipolar I within 5 years
pharmacotherapy and cognitive behavioral therapy. While D. Adolescent-onset depression typically need long-term pharmacologic
counseling Debi's parents about important issues in management to prevent relapses
management, the PMHNP advises that:
Agomelatine Brand: Valdoxan
-Melatonin multimodal (Mel-MM)
-Agonist at melatonergic 1 and melatonergic 2 receptors
-Antagonist at 5HT2C receptors
-Not FDA approved: Rx for Depression, Generalized anxiety disorder
-Initial 25 mg/day at bedtime; after 2 weeks can increase to 50 mg/day at bedtime
Amitriptyline (Elavil) Tricyclic antidepressant.
Aripiprazole (Abilify) Treatment for depression. Atypical antipsychotic. "Dopamine stabilizer". Dopamine
receptor antagonist in high concentration and also stimulates increase of dopamine
in low concentrations. Side effects: insomnia, akathisia.
Brexpiprazole (Rexulti) Treatment for depression. Atypical antipsychotic
Bupropion (Wellbutrin) Antidepressant and smoking cessation aid, It can treat depression and help people
quit smoking. It can also prevent depression caused by seasonal affective disorder
(SAD).
Citalopram (Celexa) Antidepressant, SSRI: 20-40 mg qd.
, Clomipramine (Anafranil) -Serotonin reuptake inhibitor (S-RI)
-Tricyclic antidepressant (TCA)
-Parent drug is a potent serotonin reuptake inhibitor
Active metabolite is a potent norepinephrine/noradrenaline reuptake inhibitor
-Increases serotonergic neurotransmission by blocking the serotonin reuptake pump
(transporter), -Desensitization of serotonin receptors, especially serotonin 1A
receptors
-Increases noradrenergic neurotransmission by blocking the norepinephrine
reuptake pump (transporter), -Desensitization of beta adrenergic receptors
-Dopamine is inactivated by norepinephrine reuptake in the frontal cortex
-Lacks dopamine transporters
-Increases dopamine neurotransmission in this part of the brain
**FDA Approved for Pediatrics in tx Obsessive-compulsive disorder (OCD) (ages 10
and older)
*Off-Label for Pediatric Use: Depression, Severe and treatment-resistant,
depression, Cataplexy syndrome, Anxiety, Insomnia,
Neuropathic pain/chronic pain
-Full therapeutic benefits may take 2-8 weeks
-Dosing: in Peds/Adolescents/Adults:
100-250mg/day
Cyamemazine (Tercian) Treatment for depression.
-Known as cyamepromazine
-Typical antipsychotic drug of the phenothiazine class.
-Treatment for schizophrenia
and psychosis-associated
anxiety
-Behaves like an atypical
antipsychotic, due to its
potent anxiolytic effects (5-HT2C) and lack of extrapyramidal side effects (5-HT2A).
-Conventional antipsychotic (neuroleptic, phenothiazine, dopamine 2 antagonist,
serotonin dopamine antagonist)
-Commonly Prescribed for (not FDA approved):
-Schizophrenia
-Anxiety associated with psychosis (short-term)
-Anxiety associated with nonpsychotic disorders, including mood disorders and
personality disorders (short-term)
-Severe depression
-Bipolar disorder
-Other psychotic disorders
-Acute agitation/aggression (injection)
-Benzodiazepine withdrawal
Desiprimine (Norpramine) Treats depression
Brand: Norpramin
-TCA
-Norepinephrine noradrenaline reuptake inhibitor.
-FDA approved for treating depression.
-Off-label: Anxiety, Insomnia,
Neuropathic pain/chronic pain, Treatment-resistant depression.
-More potent inhibitor of norepinephrine reuptake pump than serotonin reuptake
pump (serotonin transporter).
-May have immediate effects in treating insomnia or anxiety.
-If it is not working within 6-8 weeks for depression, it may require a dosage
increase or it may not work at all
-100-200 mg/day (for depression)
50-150 mg/day (for chronic pain).
Desvenlafaxine (Pristiq) Dual serotonin and norepinephrine reuptake inhibitor-often classified as an
antidepressant.
-FDA approved to tx MDD.
-Off-label: Vasomotor sx's, fibromyalgia, GAD, Social Anx d/o, panic d/o, PTSD,
PMDD
-Dopamine is inactivated by norepinephrine reuptake in frontal cortex (which lack
dopamine transporters) med can increase dopamine neurotransmission in this part
of the brain
-
Week 7
(2026-2027)
Complete Questions and Answers(Verified) |
Updated | Grade A+
,Question 18: A. Dissociative disorders
Christine is a 9-year-old female who presents for care after B. Post-traumatic stress disorder
having been placed in the local foster care system. She C. Impulse-control disorder
has been in and out of foster care for the last 4 years after D. Attachment disorder
her parents were killed in an automobile accident.
Christine has been placed in a variety of homes and
residential care facilities. The PMHNP recognizes that
Christine is at high risk for:
Question 7: A. Caylee is at high risk for suicide and precautions should be taken
Caylee is a 5-year-old girl who is referred for evaluation by B. The hallucinations are consistent with brief psychotic disorder or schizophrenia
child protective services. She was recently removed from C. The history and reported symptoms are typical of depressive disorder in young
her biological family and placed in foster care, as her home children
environment was reportedly unsafe due to conditions of D. This is a common situation when prepubertal children are removed from the
extreme neglect. Her foster mother reports that Caylee is biological parents regardless of how dysfunctional they are
very quiet and withdrawn and always appears sad and
disinterested in her surroundings; however, she becomes
very irritable when anything unexpected or unplanned
occurs. The foster mother became very concerned when it
appeared that Caylee was hallucinating. The PMHNP
considers that:
Question 2: A. There is a > 50% likelihood that Debi's younger sibling will develop depressive
Debi is a 15-year-old girl who is currently being treated for symptoms
depression. Her parents have been very proactive and B. The mean length of major depressive episode in adolescents is 4 months
involved in her care, and Debi has achieved remission 2 C. 20 to 40% of adolescents who have major depressive disorder will develop
months after beginning treatment with a combination of bipolar I within 5 years
pharmacotherapy and cognitive behavioral therapy. While D. Adolescent-onset depression typically need long-term pharmacologic
counseling Debi's parents about important issues in management to prevent relapses
management, the PMHNP advises that:
Agomelatine Brand: Valdoxan
-Melatonin multimodal (Mel-MM)
-Agonist at melatonergic 1 and melatonergic 2 receptors
-Antagonist at 5HT2C receptors
-Not FDA approved: Rx for Depression, Generalized anxiety disorder
-Initial 25 mg/day at bedtime; after 2 weeks can increase to 50 mg/day at bedtime
Amitriptyline (Elavil) Tricyclic antidepressant.
Aripiprazole (Abilify) Treatment for depression. Atypical antipsychotic. "Dopamine stabilizer". Dopamine
receptor antagonist in high concentration and also stimulates increase of dopamine
in low concentrations. Side effects: insomnia, akathisia.
Brexpiprazole (Rexulti) Treatment for depression. Atypical antipsychotic
Bupropion (Wellbutrin) Antidepressant and smoking cessation aid, It can treat depression and help people
quit smoking. It can also prevent depression caused by seasonal affective disorder
(SAD).
Citalopram (Celexa) Antidepressant, SSRI: 20-40 mg qd.
, Clomipramine (Anafranil) -Serotonin reuptake inhibitor (S-RI)
-Tricyclic antidepressant (TCA)
-Parent drug is a potent serotonin reuptake inhibitor
Active metabolite is a potent norepinephrine/noradrenaline reuptake inhibitor
-Increases serotonergic neurotransmission by blocking the serotonin reuptake pump
(transporter), -Desensitization of serotonin receptors, especially serotonin 1A
receptors
-Increases noradrenergic neurotransmission by blocking the norepinephrine
reuptake pump (transporter), -Desensitization of beta adrenergic receptors
-Dopamine is inactivated by norepinephrine reuptake in the frontal cortex
-Lacks dopamine transporters
-Increases dopamine neurotransmission in this part of the brain
**FDA Approved for Pediatrics in tx Obsessive-compulsive disorder (OCD) (ages 10
and older)
*Off-Label for Pediatric Use: Depression, Severe and treatment-resistant,
depression, Cataplexy syndrome, Anxiety, Insomnia,
Neuropathic pain/chronic pain
-Full therapeutic benefits may take 2-8 weeks
-Dosing: in Peds/Adolescents/Adults:
100-250mg/day
Cyamemazine (Tercian) Treatment for depression.
-Known as cyamepromazine
-Typical antipsychotic drug of the phenothiazine class.
-Treatment for schizophrenia
and psychosis-associated
anxiety
-Behaves like an atypical
antipsychotic, due to its
potent anxiolytic effects (5-HT2C) and lack of extrapyramidal side effects (5-HT2A).
-Conventional antipsychotic (neuroleptic, phenothiazine, dopamine 2 antagonist,
serotonin dopamine antagonist)
-Commonly Prescribed for (not FDA approved):
-Schizophrenia
-Anxiety associated with psychosis (short-term)
-Anxiety associated with nonpsychotic disorders, including mood disorders and
personality disorders (short-term)
-Severe depression
-Bipolar disorder
-Other psychotic disorders
-Acute agitation/aggression (injection)
-Benzodiazepine withdrawal
Desiprimine (Norpramine) Treats depression
Brand: Norpramin
-TCA
-Norepinephrine noradrenaline reuptake inhibitor.
-FDA approved for treating depression.
-Off-label: Anxiety, Insomnia,
Neuropathic pain/chronic pain, Treatment-resistant depression.
-More potent inhibitor of norepinephrine reuptake pump than serotonin reuptake
pump (serotonin transporter).
-May have immediate effects in treating insomnia or anxiety.
-If it is not working within 6-8 weeks for depression, it may require a dosage
increase or it may not work at all
-100-200 mg/day (for depression)
50-150 mg/day (for chronic pain).
Desvenlafaxine (Pristiq) Dual serotonin and norepinephrine reuptake inhibitor-often classified as an
antidepressant.
-FDA approved to tx MDD.
-Off-label: Vasomotor sx's, fibromyalgia, GAD, Social Anx d/o, panic d/o, PTSD,
PMDD
-Dopamine is inactivated by norepinephrine reuptake in frontal cortex (which lack
dopamine transporters) med can increase dopamine neurotransmission in this part
of the brain
-
